Sign In
NASDAQ:ANIK
Anika Therapeutics Inc. Stock Earnings Reports
$15.49
+0.0700 (+0.454%)
At Close: Mar 24, 2025
Anika Therapeutics. Earnings Calls
Q4 2024
Missed
-$0.0300 (-200.00%)
| Release date | Mar 12, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0300 |
| EPS Surprise | -200.00% |
| Revenue estimate | 28.125M |
| Revenue actual | 119.907M |
| Revenue Surprise | 326.34% |
Q3 2024
Missed
-$0.250 (-183.33%)
| Release date | Oct 31, 2024 |
| EPS estimate | $0.300 |
| EPS actual | -$0.250 |
| EPS Surprise | -183.33% |
| Revenue estimate | 29M |
| Revenue actual | 38.753M |
| Revenue Surprise | 33.63% |
Q2 2024
Missed
$0.170 (-26.09%)
| Release date | Aug 08, 2024 |
| EPS estimate | $0.230 |
| EPS actual | $0.170 |
| EPS Surprise | -26.09% |
| Revenue estimate | 42.1M |
| Revenue actual | 41.921M |
| Revenue Surprise | -0.425% |
Q1 2024
Missed
-$0.310 (-63.16%)
| Release date | May 08, 2024 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.310 |
| EPS Surprise | -63.16% |
| Revenue estimate | 39.21M |
| Revenue actual | 40.523M |
| Revenue Surprise | 3.35% |
Last 4 Quarters for Anika Therapeutics.
Below you can see how ANIK performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Missed
| Release date | May 08, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $28.47 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.310 |
| EPS surprise | -63.16% |
| Date | Price |
|---|---|
| May 02, 2024 | $27.59 |
| May 03, 2024 | $27.59 |
| May 06, 2024 | $27.86 |
| May 07, 2024 | $28.36 |
| May 08, 2024 | $28.47 |
| May 09, 2024 | $25.26 |
| May 10, 2024 | $25.63 |
| May 13, 2024 | $25.56 |
| May 14, 2024 | $25.59 |
| 4 days before | 3.19% |
| 4 days after | -10.12% |
| On release day | -11.28% |
| Change in period | -7.25% |
Q2 2024
Missed
| Release date | Aug 08, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $25.68 |
| EPS estimate | $0.230 |
| EPS actual | $0.170 |
| EPS surprise | -26.09% |
| Date | Price |
|---|---|
| Aug 02, 2024 | $26.00 |
| Aug 05, 2024 | $25.75 |
| Aug 06, 2024 | $26.07 |
| Aug 07, 2024 | $25.95 |
| Aug 08, 2024 | $25.68 |
| Aug 09, 2024 | $25.68 |
| Aug 12, 2024 | $25.07 |
| Aug 13, 2024 | $25.01 |
| Aug 14, 2024 | $25.29 |
| 4 days before | -1.23% |
| 4 days after | -1.52% |
| On release day | 0% |
| Change in period | -2.73% |
Q3 2024
Missed
| Release date | Oct 31, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $17.11 |
| EPS estimate | $0.300 |
| EPS actual | -$0.250 |
| EPS surprise | -183.33% |
| Date | Price |
|---|---|
| Oct 25, 2024 | $24.32 |
| Oct 28, 2024 | $24.66 |
| Oct 29, 2024 | $24.52 |
| Oct 30, 2024 | $24.68 |
| Oct 31, 2024 | $17.11 |
| Nov 01, 2024 | $16.53 |
| Nov 04, 2024 | $17.07 |
| Nov 05, 2024 | $16.30 |
| Nov 06, 2024 | $17.27 |
| 4 days before | -29.65% |
| 4 days after | 0.94% |
| On release day | -3.39% |
| Change in period | -28.99% |
Q4 2024
Missed
| Release date | Mar 12, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $17.11 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0300 |
| EPS surprise | -200.00% |
| Date | Price |
|---|---|
| Mar 06, 2025 | $17.00 |
| Mar 07, 2025 | $16.62 |
| Mar 10, 2025 | $16.50 |
| Mar 11, 2025 | $16.79 |
| Mar 12, 2025 | $17.11 |
| Mar 13, 2025 | $15.21 |
| Mar 14, 2025 | $15.91 |
| Mar 17, 2025 | $16.11 |
| Mar 18, 2025 | $15.86 |
| 4 days before | 0.647% |
| 4 days after | -7.31% |
| On release day | -11.10% |
| Change in period | -6.71% |
Anika Therapeutics. Earnings Call Transcript Summary of Q4 2024
Divestitures: Anika has successfully divested Arthrosurface and Parcus Medical, aimed at refocusing on core hyaluronic acid (HA) products, which are anticipated to drive shareholder value.
Financial Performance Highlights:
- Q4 2024 Revenue: Achieved $30.6 million, a slight increase of 1% year-over-year. Full-year revenue was $119.9 million, a marginal decline of 1% compared to 2023.
- Commercial Channel Growth: Revenue from the commercial channel rose 25% in Q4 and 17% for the full year, indicating strong international OA pain management growth
- +22% in Q4
- +16% for full year
- OEM Channel Performance: Revenue from the OEM channel decreased by 8% in both the fourth quarter and for the full year, impacted by competitive pricing pressures and lower volumes from Johnson & Johnson’s (J&J) products.
Product Developments:
- Integrity Product Success: The Integrity implant system experienced over 40% sequential growth for three consecutive quarters, with more than 1,000 surgeries performed since launch, capturing over 1% of the US soft tissue augmentation market.
- Hyalofast & Cingal: Significant progress in regulatory submissions for Hyalofast, anticipated FDA launch by 2026. For Cingal, productive discussions with the FDA are ongoing, with feedback expected to guide future R&D expenses.
Operational Highlights:
- Cash Flow & Liquidity: Generated operating cash flow of $1.6 million in Q4, ending the quarter with $56 million in cash and no debt.
- Stock Repurchase Plan: Completed an initial $15 million share repurchase ahead of schedule, reinforcing commitment to returning value to shareholders.
Guidance and Outlook for 2025:
- Revenue Projections: Expected commercial channel revenues between $47 million and $49.5 million (up 12%-18%) while OEM channel revenues anticipated between $64 million and $68.5 million (down 12%-18%).
- Adjusted EBITDA: Anticipated between 8%-10% for 2025, influenced by ongoing investments in the regenerative solutions portfolio and competitive pressures in the OEM sector.
Long-term Growth Strategy:
Anika plans to capitalize on the growth potential of Integrity, expand international market share for OA pain products, and drive further development and approval for both Hyalofast and Cingal to enhance growth in the coming years.
Conclusion
Anika is focused on streamlining its operations and enhancing its core offerings in HA products. The company has laid a solid foundation for growth through recent product successes and strategic divestitures, aiming for enhanced shareholder value and sustainable revenue growth. The outlook for 2025 remains cautiously optimistic amidst competitive market conditions.
Anika Therapeutics. Earnings History
Earnings Calendar
FAQ
When is the earnings report for ANIK?
Anika Therapeutics Inc. (ANIK) has scheduled its earnings report for May 14, 2025 before the markets open.
What is the ANIK price-to-earnings (P/E) ratio?
ANIK P/E ratio as of Mar 24, 2025 (TTM) is -2.34.
What is the ANIK EPS forecast?
The forecasted EPS (Earnings Per Share) for Anika Therapeutics Inc. (ANIK) for the first fiscal quarter 2025 is $0.0900.
What are Anika Therapeutics Inc.'s retained earnings?
On its balance sheet, Anika Therapeutics Inc. reported retained earnings of $119.91 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
